Previous 10 | Next 10 |
SAN FRANCISCO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investigation: The investigation focuses on Y-...
Y-mAbs Therapeutics, Inc. (YMAB) Q3 2022 Earnings Conference Call November 08, 2022, 16:00 ET Company Participants Thomas Gad - Founder, Interim CEO & President Sue Smith - SVP & Chief Commercial Officer Bo Kruse - EVP, Secretary, Treasurer & CFO ...
MACK Stock Explodes 240%+ Overnight, Here Are 3 Penny Stocks To Watch Now Thanks to the 2022 stock market crash, there are plenty of penny stocks to watch. The broad market sell-off has taken even some of the most popular names and sent them below the $5 mark. That might be bad for ...
SAN FRANCISCO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/YMAB Contact An Attorney Now: YMAB@hbsslaw....
Y-mAbs Therapeutics press release ( NASDAQ: YMAB ): Q3 GAAP EPS of -$0.63 beats by $0.07 . Revenue of $12.5M (+39.4% Y/Y) beats by $0.49M . Shares +7.5% . Cash position of $114.5 million as of September 30, 2022, anticipated runway into mid-2024. ...
Q3 2022 DANYELZA® record product revenues of $12.5 million, YoY growth of 40% and 28% sequential increase compared to Q2 2022 DANYELZA marketing authorization granted in Israel; regulatory filing submitted in Brazil Management reiterates financial guidance, includin...
Boston, Massachusetts--(Newsfile Corp. - November 3, 2022) - Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law violations. Investors who have lost money in their Y-mAbs Therapeutics, Inc. investment should contact the firm to learn mor...
SAN FRANCISCO, CA / ACCESSWIRE / November 3, 2022 / - Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/YMAB Contact An Attorney Now: YMAB@hbsslaw.com 844-916...
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter that ended September 30, 2022, on Monday, November 7, 2022, after the close ...
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses to submit your losses now . Visit: www.hbsslaw.com/investor-fraud/YMAB Contact An Attorney Now: YMAB@hbsslaw....
News, Short Squeeze, Breakout and More Instantly...
Y-mAbs Therapeutics Inc. Company Name:
YMAB Stock Symbol:
NASDAQ Market:
Y-mAbs Therapeutics Inc. Website:
2024-07-05 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic pr...
Q1 2023 DANYELZA® record net product revenues of $20.3 million, driving YoY growth of 93% and a 24% sequential increase compared to Q4 2022 Management updates 2023 financial guidance, now anticipating higher DANYELZA net revenues of $80-85 million and lower cash burn of $40-50 millio...